A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, F. Cervantes, Abdel Hmissi et al.|Haematologica|2015Cited by 252